CureVac N.V. (NASDAQ:CVAC) Given Average Rating of “Hold” by Brokerages

Shares of CureVac N.V. (NASDAQ:CVAC) have been assigned an average rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.8333.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CureVac in a research report on Tuesday, December 16th.

CureVac Trading Down 0.2%

Shares of NASDAQ CVAC opened at $4.66 on Friday. The company has a current ratio of 3.70, a quick ratio of 3.69 and a debt-to-equity ratio of 0.03. CureVac has a one year low of $4.00 and a one year high of $4.68. The business has a 50-day moving average price of $4.93 and a two-hundred day moving average price of $5.24. The firm has a market capitalization of $1.05 billion, a PE ratio of 6.47 and a beta of 1.77.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings results on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $63.53 million during the quarter, compared to analyst estimates of $21.40 million. CureVac had a net margin of 199.92% and a negative return on equity of 23.03%. As a group, analysts predict that CureVac will post 0.72 earnings per share for the current fiscal year.

Institutional Trading of CureVac

A number of institutional investors have recently bought and sold shares of CVAC. Caitong International Asset Management Co. Ltd increased its position in CureVac by 354.8% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock worth $30,000 after purchasing an additional 4,375 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of CureVac in the 2nd quarter valued at approximately $35,000. Integrated Wealth Concepts LLC increased its holdings in CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after buying an additional 3,000 shares during the last quarter. Kathmere Capital Management LLC bought a new position in CureVac during the second quarter valued at approximately $60,000. Finally, L2 Asset Management LLC bought a new position in CureVac during the second quarter valued at approximately $70,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.